99767 20240319080947.0 doi 10.1080/14737167.2021.1880324 sideral 122932 ART-2022-122932 eng Taxonera, Carlos Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain 2022 Access copy available to the general public Unrestricted Background: To evaluate the cost-effectiveness of tofacitinib in comparison to vedolizumab for the treatment of moderate-to-severe ulcerative colitis (UC) after failure or intolerance to conventional therapy (bio-naive) or first-line biologic treatment (bio-experienced), from the Spanish National Health System (NHS) perspective. Methods: A lifetime Markov model with eight-week cycles was developed including five health states: remission, response, active UC, remission after surgery, and death. Response and remission probabilities (for induction and maintenance periods) were obtained from a multinomial network meta-analysis. Drug acquisition – biosimilar prices included – (ex-factory price with mandatory deductions), adminis- tration, surgery, patient management, and adverse event management costs (€, year 2019) were considered. A 3% discount rate (cost/outcomes) was applied. Probabilistic and deterministic sensitivity analyses (PSA) were conducted. Results: Tofacitinib was dominant versus vedolizumab (both in bio-naive and bio-experienced patients) entailing total cost savings of €23,816 (bio-naïve) and €11,438 (bio-experienced). Differences in quality- adjusted life-year (QALY) were smaller than 0.1 for both populations. PSA results showed that tofacitinib has a high probability of being cost-effective (bio-naïve: 82.5%; bio-experienced: 90.6%) versus vedolizumab. Conclusions: From the Spanish NHS perspective, tofacitinib could be a dominant treatment (less costly and more effective) in comparison to vedolizumab, with relevant cost savings and similar QALY gains. info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 2.3 2022 HEALTH CARE SCIENCES & SERVICES 72 / 106 = 0.679 2022 Q3 T3 HEALTH POLICY & SERVICES 59 / 87 = 0.678 2022 Q3 T3 PHARMACOLOGY & PHARMACY 200 / 278 = 0.719 2022 Q3 T3 0.596 2022 Health Policy 2022 Q2 Pharmacology (medical) 2022 Q2 Medicine (miscellaneous) 2022 Q2 3.4 2022 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion de Andrés-Nogales, Fernando García-López, Santiago Universidad de Zaragoza (orcid)0000-0003-3970-5457 Sánchez-Guerrero, Amelia Menchén, Belén Peral, Carmen Cábez, Ana Gómez, Susana López-Ibáñez de Aldecoa, Alejandra Casado, Miguel Ángel Menchén, Luis 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 22, 1 (2022), 73-83 Expert Review of Pharmacoeconomics and Outcomes Research Expert Review of Pharmacoeconomics and Outcomes Research 1473-7167 2270609 http://zaguan.unizar.es/record/99767/files/texto_completo.pdf Versión publicada 3269706 http://zaguan.unizar.es/record/99767/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:99767 articulos driver 2024-03-18-12:41:04 ARTICLE